Neuralymed
Delaware corporation · 1 known investors
Neuraly is a clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases, with a focus on inhibiting pathological glial activation to prevent neuronal cell death. The company is advancing NLY01, a candidate in Phase 2 clinical trials for Parkinson's disease.
AI & Machine LearningBiotechHealthtechMedical Devices
Founders & leadership
SL
Seulki LeeExecutive Officer
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$10.4MraisedApr 2018 · 25 investors · Other Health CareRule 506(b)
▶$10.4MraisedApr 2018 · 25 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Seulki LeeExecutive Officer, Director
- Viktor RoschkeExecutive Officer, Director
- Offering amount
- $10.4M
- Amount sold
- $10.4M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$100KraisedDec 2016 · 2 investors · Other Health CareRule 506(b)
▶$100KraisedDec 2016 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Seulki LeeExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $100K
- Minimum investment
- $10K
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.